Correspondence sudato@z3.keio.jp (T.S.), keiyot@gmail.com (K.T.) In Brief Kobayashi et al. report that a bacterial second messenger c-di-GMP influences both HSPCs and their niche cells through STING, thereby inducing expansion and mobilization of multipotent progenitors while decreasing the repopulation capacity of hematopoietic stem cells.
INTRODUCTION
Hematopoietic stem cells (HSCs) have both self-renewal and multiple differentiation capacities to replenish the entire hematopoietic system throughout the organismal lifespan (Orkin and Zon, 2008) . While HSCs remain quiescent in terms of the cell cycle at a steady state, they rapidly re-enter the cell cycle to generate differentiated hematopoietic cells in a demand-driven manner following exposure to various stimuli, including cytotoxic agents, irradiation, and infectious stresses (Blanpain et al., 2011) . Upon systemic infection by external pathogens, peripheral immune cells are challenged and rapidly consumed, requiring a continuous supply of leukocytes. Hematopoietic stem and progenitor cells (HSPCs) play a major role in supplying these peripheral immune cells. Various inflammatory cytokines and interferons (IFNs) from immune or infected cells reportedly induce both HSPC cycling and their homing to infectious sites (King and Goodell, 2011) . In addition to cytokines, pathogenassociated molecular patterns (PAMPs), including lipopolysaccharide (Nagai et al., 2006) , directly stimulate HSPCs through specific pathogen recognition receptors. However, the mechanisms underlying HSPC activity following infectious stress in vivo remain elusive. Bis-(3 0 -5 0 )-cyclic dimeric guanosine monophosphate (c-di-GMP) is a second messenger that is utilized ubiquitously by prokaryotes and is associated with numerous bacterial activities, including motility, biofilm formation, and pathogenesis (Hengge, 2009 ). In addition to its role as a bacterial second messenger, c-di-GMP was recently recognized as an immunestimulating molecule in mammalian cells (Karaolis et al., 2007) . The endoplasmic protein stimulator of IFN genes (STING, also designated TMEM173) was originally identified as an adaptor protein essential for the innate immune response against cytosolic DNA (Ishikawa and Barber, 2008; Zhong et al., 2008) . STING is also recognized as an endogenous c-di-GMP receptor, sharing the same signaling pathway with the cytosolic DNAsensing mechanism (Burdette et al., 2011) . Thus, it is essential to determine whether the c-di-GMP/STING pathway functions in host defense mechanisms against bacterial infection and, if so, how that activity affects HSPCs.
In this study, we identify c-di-GMP as a signal-transducing PAMP for HSPCs. We report that c-di-GMP alters HSPC kinetics and dynamics through the STING pathway, promoting cell cycle entry and expansion of multipotent progenitors (MPPs) as well as mobilization of HSPCs into the spleen. Furthermore, we show that c-di-GMP modulates the bone marrow (BM) microenvironment to induce HSPC mobilization. Overall, we propose that c-di-GMP is a crucial regulator of HSPCs following bacterial infection.
RESULTS

Bacterial Infection Decreases the Number of Long-Term Hematopoietic Stem Cells
To determine how HSPCs respond to septicemia, we used a murine cecal ligation and puncture (CeLP) model to induce poly-microbial intraperitoneal infection ). The number of white blood cells (WBCs) (especially granulocytes) and platelets significantly decreased 48 hr after CeLP, consistent with observations in mice with severe sepsis (Figure 1A) . BM cellularity did not significantly decrease ( Figure 1B ), but, as in peripheral blood (PB), the number of granulocytes decreased while the number of monocytes increased (data not shown). The number of Lin significantly decreased when compared with the sham-surgery group. The CeLP group showed an activated cell-cycle status in each HSPC fraction examined ( Figure 1G ). To assess HSPC behavior following infectious stress, we subjected mice to Salmonella infection, which induces septicemia, and determined the HSPC number 5 days later ( Figure S1A ). Similar to CeLP, the number of cells in the LSK fraction, especially MPPs, expanded (Figures S1B-S1D), whereas enriched HSC fractions decreased (Figures S1D and S1E) . These findings support the idea that HSPCs directly respond to systemic bacterial infection and that the MPP fraction expands at the expense of the LT-HSC fraction.
c-di-GMP Administration Mimics Bacterial Infection
Toll-like receptor (TLR) signaling and type I IFN signaling are dispensable for HSPC expansion in a CeLP model (Scumpia et al., 2010) ; therefore, we speculated that other bacteria-specific molecules that circumvent conventional TLR signaling pathways must target HSPCs to stimulate expansion. The c-di-GMPactivated STING/Irf3 axis senses cytosolic DNA independent of TLR signaling (Ishikawa and Barber, 2008; Zhong et al., 2008) ; therefore, we focused on c-di-GMP as a candidate molecule that could affect HSPC kinetics. To analyze an effect of c-di-GMP on hematopoiesis in vivo, we administered c-di-GMP to mice ( Figure 2A ). WBC counts, hemoglobin levels, and platelet counts were transiently halved 3 days after c-di-GMP treatment ( Figure S2A ). The number of bone marrow mononuclear cells (BMMNCs) also decreased ( Figure 2B ). The frequency of lymphocytes decreased, whereas myeloid cells increased 3 days after c-di-GMP treatment ( Figure S2B ). However, the number of cells in each differentiated fraction decreased upon c-di-GMP treatment ( Figure S2B ). Thus, c-di-GMP treatment faithfully mimics the conditions associated with transient pancytopenia observed following severe sepsis, prolonged infection, and immune dysregulation (King and Goodell, 2011) .
c-di-GMP Alters HSPC Number and Function in the BM We next examined the effect of c-di-GMP on immature hematopoietic fractions in the BM. c-di-GMP treatment induced a striking reduction in the number and frequency of all these progenitors in the BM ( Figure S2C ). c-di-GMP decreased the HSC-enriched fraction in number and frequency (Figures 2C and 2D) . Analysis of the LSK fraction revealed that c-di-GMP treatment upregulated Sca-1 expression in a manner similar to that reported following IFN stimulation (Pietras et al., 2014) 2H , and S2E). Overall, the number of HSCs decreased following c-di-GMP treatment. Furthermore, upon bone marrow transplantation (BMT), c-di-GMP-treated BM cells showed a reduced repopulation capacity ( Figure 2I ), supporting the idea that the number of functional HSCs decreases following c-di-GMP treatment, as reported for HSPCs in a sepsis model (Burberry et al., 2014) . However,
following c-di-GMP treatment showed a repopulation capacity comparable to that of control cells, except for at 1 month after BMT ( Figure 2J ), suggesting that anomalous HSC activity is transient. By contrast, in c-di-GMP-treated mice, the frequency and number of MPPs, which give rise to all hematopoietic lineages but have a limited self-renewal capacity, exceeded that seen in control mice ( Figures 2C and 2D ). We also confirmed that the frequency of MPPs, defined as CD34 +
Flt3
+ LSK cells, increased upon c-di-GMP treatment ( Figure S2F ). We next examined the effect of c-di-GMP treatment on MPP function, as indicated by short-term reconstitution and in vitro clonogenic capacity. Both CD150 + CD41/CD48 + LSK cells and CD34 + Flt3 + LSK cells from c-di-GMP-treated Ubc-GFP reporter mice, which ubiquitously express GFP, showed reduced short-term reconstitution of myeloid/lymphoid/erythroid/platelet cells ( Figure 2K ). In addition, colonies derived from single MPPs of c-di-GMP-treated mice were primarily granulocytes and the number of cells per colony was lower than that in controls and was similar to that in the LKS À fraction. By contrast, STING-deficient cells showed a comparable colony-forming capacity in the presence or absence of c-di-GMP ( Figure S2G ). This result does not exclude the possibility that LKS À cells contaminated the LSK fraction.
Given that LKS À cells do not express Flt3, we conclude that following c-di-GMP treatment, the frequency of CD34 + Flt3 + MPP cells increased while their reconstitution potential in BM decreased.
c-di-GMP Dampens the Cell-Cycle Quiescence, Reconstitution Capacity, and Metabolic Status of HSPCs We next asked how c-di-GMP treatment altered HSC number and function. We assessed the cell-cycle status of HSPCs using short-term bromodeoxyuridine (BrdU) incorporation assays.
c-di-GMP induced the proliferation of primitive HSCs, but not of other HSPCs ( Figure 2L ). Metabolic analysis of HSPCs from c-di-GMP-treated mice revealed reduced intracellular ATP levels and increased lactate dehydrogenase (LDH) activity (Figures S2H and S2I) in STING +/+ HSCs and MPPs, which was not seen in STING À/À cells. Several glycolytic genes and tricarboxylic acid (TCA) cycle-associated genes were also inversely regulated in STING +/+ cells ( Figure S2J ). On the other hand, no significant increase in apoptotic cells was detected in the HSPC See also Figure S1 . (legend continued on next page) fraction, suggesting that the decreased HSPC number and frequency is not attributable to the induction of apoptosis (Figure S2K) . In agreement, expression levels of apoptosis-related genes in purified HSCs were not significantly upregulated after c-di-GMP treatment ( Figure S2L ). By contrast, expression levels of cyclin-dependent kinase inhibitors were consistently decreased in HSCs relative to controls after c-di-GMP treatment ( Figure 2M ). Collectively, these findings indicate that c-di-GMP treatment induces the entry of HSCs into the cell cycle rather than apoptosis. Importantly, the endogenous STING ligand, cGAMP (Ablasser et al., 2013) , elicited HSPC responses less potently than c-di-GMP ( Figure S2M ), suggesting a c-di-GMPspecific role in anti-microbial defense systems other than cGAS-mediated anti-double-stranded DNA responses.
c-di-GMP Induces HSPC Expansion in the Spleen
Given that c-di-GMP is potentially an immunostimulatory molecule, we hypothesized that it activates HSPC egress from the BM. We first performed histological observation of the spleen with or without c-di-GMP treatment. As expected, we observed spleen hematopoiesis marked by the presence of megakaryocytes in the red pulp, with slight destruction of the white pulp architecture ( Figure 3A ). There was a significant increase in spleen weight ( Figure S3A ) and MPP frequency and number compared with controls ( Figures 3B and 3C ; data not shown), while HSCs and differentiated cells did not show a significant increase , indicating that c-di-GMP-induced expansion is prominent in MPP fractions. Upon transplantation of splenocytes into lethally irradiated mice, the control group died by day 12, whereas 62.5% of mice transplanted with cells from c-di-GMP-treated mice survived ( Figure 3G ), indicating that functional HSPCs had been mobilized to the spleen. Intriguingly, however, the long-term reconstitution of purified HSCs did not significantly differ between spleen cells from c-di-GMPtreated and control groups ( Figure S3D ), in accordance with the comparable number of HSCs between the two groups in the spleen. Use of a larger sample size (n = 26) enabled us to detect increases in splenic HSC number following c-di-GMP treatment ( Figure S3F ). On the other hand, MPPs from c-di-GMP-treated Ubc-GFP reporter mice showed enhanced shortterm reconstitution of PB cells, in sharp contrast to BM MPPs ( Figures 2K and 3G ). The in vitro differentiation capacity of single STING +/+ or STING À/À MPPs did not markedly differ between control and c-di-GMP-treated groups ( Figure S3H ). The frequency ( Figure S3G ) and colony-forming capacity (Figures S3I and S3J) of HSPC fractions also increased in PB after c-di-GMP treatment, suggesting that immature HSPCs are mobilized to the periphery after c-di-GMP administration. However, BrdU analysis showed that CD150 + CD41/CD48 + LSK cells in the spleen robustly accumulated BrdU following c-di-GMP treatment, suggesting that both migration and proliferation underlie the increase in splenic MPPs ( Figure S3K ). Of note, cGAMP did not sufficiently increase the number of splenic HSPCs compared to c-di-GMP ( Figure S3L ).
c-di-GMP Activates the Irf3/Type I IFN Axis in LT-HSCs through STING We performed a cDNA microarray followed by gene set enrichment analysis (GSEA) on purified LT-HSCs to examine which pathway is activated following c-di-GMP treatment in vivo. IFN-a response genes and Irf3 target genes were significantly enriched in the c-di-GMP treatment group ( Figure 4A ). Using real-time qPCR, we confirmed that both STING and Irf3 were highly expressed in HSPC fractions, including LT-HSCs, at levels comparable to or even higher than those in BM-derived macrophages ( Figure 4B ).
In STING À/À mice, the numbers of HSCs and MPPs were unchanged following c-di-GMP treatment ( Figure 4C ). In addition, phenotypic HSPC expansion in the spleen was abrogated in c-di-GMP-treated STING À/À mice ( Figure 4D ). Thus, the effects Figure S4G ), whereas both phenotypic HSCs and MPPs markedly expanded in the spleen ( Figure S4H ). On the other hand, inhibition of NF-kB, another downstream STING target, by the IKKa inhibitor Bay11-7082 almost completely rescued the effects of c-di-GMP, suggesting that NF-kB signaling downstream of c-di-GMP/STING is an important regulator of HSPC behavior ( Figures S4I and S4J) . Notably, however, c-Kit expression was decreased in c-di-GMP-or Bay11-7082-treated mice (data not shown), making it difficult to accurately determine the number of HSPCs. Figure 5J ) and HSPC expansion in the spleen was abrogated following c-di-GMP treatment (Figure 5K) . Collectively, in addition to cell-autonomous activity, STING controls the HSPC pool size in the BM and spleen in a non-cell-autonomous manner. To further test the cell-autonomous effects of c-di-GMP on HSPCs, we established chimeric mice whose BM contained a 1:1 ratio of STING +/+ and STING À/À cells and treated them with c-di-GMP ( Figure S5G ).
Following treatment, BM chimerism of STING À/À donor-derived myeloid and B cells was decreased, suggesting that, in addition to its direct impairment of HSC function, the cell-autonomous and non-cell-autonomous effects of c-di-GMP treatment favor myeloid and B cell production, presumably through the migration of MPP cells to the periphery ( Figure S5H ).
c-di-GMP Attenuates the Niche Function of Mesenchymal Stromal Cells in BM
We next sought to define the mechanisms underlying HSPC egress from the BM. HSCs reside in specialized BM niches that regulate the balance between self-renewal and differentiation, and the ablation of niche cells promotes loss of quiescence and HSC mobilization (Mé ndez-Ferrer et al., 2010) , effects comparable to those observed following c-di-GMP administration. BM architecture was drastically changed by c-di-GMP treatment, with a massive decrease in cellularity and an increase in the size of the sinusoidal area surrounded by PLVAP + endothelial cells ( Figures 6A-6C ). This change in sinusoidal architecture was also observed in Ifnar1 À/À mice, Irf3 À/À :Irf7 À/À mice, and STING À/À BM chimeric mice, whereas STING À/À mice showed no structural changes ( Figure S6A ), suggesting a STING-dependent Ifnar1/Irf3/Irf7-independent effect of c-di-GMP on non-hematopoietic cells. These changes motivated us to examine the frequency and number of several types of HSPC niche cells that reportedly reside in the BM, including endothelial cells, osteoblastic progenitor cells, and mesenchymal stromal cells (MSCs) , which essentially overlap with CXCL12-abundant reticular cells (Omatsu et al., 2010) and CD45 À Ter119 À LepR + cells (Zhou et al., 2014) . Every non-hematopoietic niche cell type showed a significant decrease in both frequency and number after c-di-GMP treatment ( Figures  6D and 6E ), suggesting that deformation of multiple niche components promotes HSPC detachment from the BM.
Among BM non-hematopoietic cells, platelet-derived growth factor receptor (PDGFR)a + integrin aV (CD51) + MSCs , mono), and BM-derived macrophages (Mac), were analyzed by qPCR. Each value was normalized to b-actin expression and is expressed as the fold difference compared to levels in LT-HSC samples (mean ± SD, n = 4).
(legend continued on next page) expressed the highest levels of STING and Irf3 ( Figure 6F ), suggesting that, in addition to hematopoietic cells, MSCs are a primary target of STING-mediated signaling, and that the decrease in the number of other cell types could be ascribed to non-cell-autonomous mechanisms. We then quantified the expression levels of specific factors that maintain HSC function or anchor cells to the niche in sorted niche cells upon c-di-GMP treatment. KitL, CXCL12, Angpt1, and VCAM1 expression levels invariably decreased following the treatment of MSCs ( Figure 6G ). Importantly, MSC expression of factors that maintain HSPCs was lower in c-di-GMP-treated Ifnar1 À/À mice than in similarly treated controls ( Figure 6G ). This result indicates that c-di-GMP treatment attenuates HSPC maintenance and anchoring in the BM niche and that the underlying mechanism is type I IFN independent. HSCs co-cultured with CMA-treated OP9 cells showed a dose-dependent decrease in colony number, confirming a negative effect on niche function ( Figure S6B ).
We also asked whether the splenic niche, where mobilized HSPCs colonize, is altered in response to c-di-GMP. Indeed, although the microscopic architecture of the splenic niche was not deformed following c-di-GMP administration ( Figure S6C ), the number of non-hematopoietic cells significantly increased in the spleen ( Figures S6D and S6E ).
Signaling via TGF-b and G-CSF Is Essential for c-di-GMP-Dependent HSPC Expansion in the Spleen
To define the downstream targets of c-di-GMP, we performed GSEA of cDNA microarray data obtained from c-di-GMP-treated or non-treated MSCs. TGF-b signaling, as well as type I IFN, NFkB, p38 MAPK, and fibroblast growth factor (FGF) signaling, was upregulated ( Figures 7A and S7A ). In addition, phosphorylation of ERK1/2 and AKT, which are downstream targets of FGF, was not altered in MSCs after c-di-GMP treatment ( Figure S7C ). Thus, we tested the effect of TGF-b signaling on HSPCs by c-di-GMP. TGF-b promotes osteoblastic differentiation through phosphorylation of Smad2 and Smad3 (Chen et al., 2012) . Accordingly, mRNAs encoding osteoblastic transcription factors were invariably upregulated in c-di-GMP-treated MSCs, whereas adipogenesis-related genes were downregulated (Figures 7B and S7B) .
Smad2 exhibited focal activation in steady-state conditions as previously reported (Brenet et al., 2013) , while phosphoSmad2 was globally upregulated after c-di-GMP treatment ( Figures 7C and 7D) , an effect observed in Ifnar1 À/À and
Irf3
À/À
:Irf7 À/À mice ( Figure S7D ). Although TGF-b alone was not sufficient to alter HSPC dynamics in the BM and spleen ( Figures S7E-S7G ), TGF-b receptor 1 inhibition decreased MPPs in the spleen upon c-di-GMP treatment, albeit with no obvious change in BM HSPCs ( Figures 7E-7G ). We conclude that TGF-b signaling is essential for HSPC expansion in the spleen but does not alter the HSPC pool size in the BM. We next sought to identify cytokines that stimulate BM HSPC function. Serum levels of G-CSF were increased in c-di-GMP-treated mice, whereas levels of other inflammatory cytokines were not ( Figure S7H) . Accordingly, c-di-GMP treatment reduced HSPC mobilization in G-CSF receptor-deficient mice (Csf3r À/À ), whereas HSPC fractions in BM did not show similar effects (Figures S7I and S7J) , suggesting that G-CSF is a c-di-GMP target. However, Smad2 phosphorylation was observed in Csf3r À/À mice ( Figure S7D ), suggesting that G-CSF and TGF-b independently regulate HSPC expansion in the spleen.
DISCUSSION
In this study, we identified crucial roles for c-di-GMP/STING signaling in the dynamics of hematopoiesis through modulation of HSPCs and their niches. A previous observation that HPSC expansion under infectious stress occurs even in the absence of TLR signaling or type I IFN responses indicated that unknown bacteria-derived factors activate a signal that stimulates HSPC expansion (Scumpia et al., 2010) . Our results suggest that c-di-GMP is a bacteria-derived activator of this expansion that acts via the induction of extramedullary hematopoiesis and modulation of the BM microenvironment through STING.
c-di-GMP/STING Signaling Induces MPP Expansion in the Periphery and Decreases the Number of LT-HSCs c-di-GMP treatment decreased the number of various hematopoietic cells, including LT-HSCs, in vivo. Notably, c-di-GMP suppressed the reconstitution capacity and cell-cycle quiescence of LT-HSCs, whereas it substantially increased the MPP number in the spleen, an effect likely due to the mobilization and proliferation of MPPs. Although we could not calculate the precise number of MPPs in the BM due to potential contamination by the LKS À fraction, as it has been reported that the LKS À fraction can contaminate MPPs in BM for IFNstimulated HSPCs (Pietras et al., 2014) , the short-term reconstitution capacity was potentiated in splenic MPPs. This finding supports the idea that splenic HPSCs function to supply immune cells in peripheral tissues through cell division (Massberg et al., 2007) . In contrast to c-di-GMP treatment, the number of HSPCs in STING À/À mice subjected to CeLP was comparable to that in (legend continued on next page) (Pietras et al., 2014; Verma et al., 2002) , an activity that requires p38 MAPK activation in part. Another possible mechanism is upregulation of a systemic inflammatory response. Irf3 reportedly interferes with expression of the p40 subunit of interleukin (IL)-12, thereby limiting T helper type 1 cell (TH1) and IL-17-producing helper T cell (TH17) activation upon viral infection (Negishi et al., 2012) . Thus, in turn, c-di-GMP treatment may have augmented a systemic inflammatory response in Irf3 À/À , Irf3 À/À :Irf À/ÀÀ , and Ifnar1 À/À mice (Sato et al., 2009 ). 
TGF-b Signaling Is Essential for MPP Expansion in the
Spleen by c-di-GMP/STING Signaling TGF-b maintains HSC function in a steady state and facilitates restoration of HSC quiescence under stress conditions (Brenet et al., 2013) . We demonstrated that TGF-b activation is also required for HSPC expansion in the spleen following c-di-GMP treatment, an effect presumably due to altered MSC function. TGF-b treatment alone had a minimal mobilizing effect on HSPCs compared with activation of type I IFN, NF-kB, or p38 MAPK, downregulation of Notch activity, or G-CSF overproduction. Nonetheless, TGF-b activity may cooperate with these factors to alter HSPC number and/or function through c-di-GMP-STING signaling. Given the global upregulation of TGF-b in the BM following c-di-GMP treatment independent of G-CSF signaling, we do not exclude the possibility that TGF-b activates a mechanism intrinsic to HSPCs that promotes their mobilization, although gene expression profile data do not support this conclusion.
This study reports how the bacteria-derived molecule c-di-GMP governs HSPC dynamics following infection independent of TLR and IFN signaling. c-di-GMP/STING signaling activates various pathways in multiple cell types, including type I IFN signaling and alteration of MSC function, to efficiently expand and relocalize hematopoietic precursors, which would modulate a robust response of HSPCs to bacterial infection. c-di-GMP promotes cell-cycle entry and HSC mobilization; therefore, a c-di-GMP mimetic or STING agonist could act as a novel HSPC modulator. Further investigation of the activity and regulation of c-di-GMP and its downstream signals should benefit our understanding of the relationship between the pathophysiology of bacterial infection and HSPC dynamics.
EXPERIMENTAL PROCEDURES
Mice C57BL/6J mice (8-12 weeks old) were used in all experiments, unless otherwise stated. C57BL/6-Ly5.1 congenic mice were used for competitive repopulation assays. Irf3-deficient mice and Irf3/Irf7-deficient mice (Honda et al., 2005) were kindly provided by Dr. Tadatsugu Taniguchi (University of Tokyo). STING-deficient mice (Ishikawa and Barber, 2008) were kindly provided by Dr. Takashi Saito (RIKEN) with the permission of Dr. Glen Barber (University of Miami). IFNAR1-deficient mice (Mü ller et al., 1994) were purchased from The Jackson Laboratory. Evi1-GFP reporter mice (Kataoka et al., 2011) were provided by Dr. Mineo Kurokawa (University of Tokyo). Ubc-GFP reporter mice (Schaefer et al., 2001) were purchased from The Jackson Laboratory. CSF3R-deficient mice (Liu et al., 1996) were provided by Dr. Shinsuke Yuasa (Keio University). All procedures were performed in accordance with the guidelines of Keio University School of Medicine. For detailed methods, see Supplemental Experimental Procedures.
ACCESSION NUMBERS
The GEO accession number for the microarray data used in this study is GSE65905. 
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Supplemental Experimental Procedures
Reagents and antibodies
Cyclic-di-GMP was synthesized as described previously (Hyodo and Hayakawa, 2004) Fluor 488-conjugated anti-rabbit IgG were used. Murine TGF-β1 (R&D systems) was dissolved in PBS to a final concentration of 4 µg/mL. For the CMA (Sigma Aldrich) assay, CMA was dissolved in DMSO to a concentration of 1 M. For the TGF-β1 inhibition assay, Ly364947 (Sigma Aldrich) was dissolved in DMSO to a final concentration of 2.5 mg/mL. For the NF-κB inhibition assay, Bay11-7082 (Sigma Aldrich) was dissolved in DMSO to a final concentration of 2 mg/mL.
CeLP model
To induce polymicrobial sepsis, mice underwent CeLP or a sham procedure ) with modifications. Mice were anesthetized using pentobarbital, an incision was made at the midline of the abdomen, and the cecum was pulled out from the peritoneal cavity. At 7 mm from the distal tip, the cecum was ligated, punctured twice using 25G needles (Terumo), and placed back into the abdomen, and the abdominal wall was then sutured.
Flow cytometry
HSC fractions were analyzed essentially as described previously (Arai et al., 2004) , and CD127 hi Lin -c-Kit int Sca-1 lo common lymphoid progenitors (Kondo et al., 2000) . As for niche cells, endothelial cells (Ding et al., 2012) , osteoblastic progenitor cells (Nakamura et al., 2010) , and MSCs Hoechst 33342 as previously described (Arai et al., 2004) . Data were analyzed using FlowJo™ software (Tree Star Inc.).
Cell cycle analysis
For c-di-GMP experiments, mice (9-12-week-old) were intraperitoneally injected with 1 mg of BrdU dissolved in 1 mL of PBS every 12 hours for a total of six injections. Experimental and control mice were co-injected with c-di-GMP (200 nmol) or PBS, respectively, at the first BrdU injection. For CeLP experiments, mice were injected with 1 mg of BrdU dissolved in 1 mL of PBS every 8 hours starting 24 hours after the operation for a total of three injections. In both experiments, mice were sacrificed 12 hours after the final injection. For cell cycle analysis by flow cytometry, cells were first stained with antibodies recognizing surface markers and then fixed and permeabilized using a BrdU Flow Kit (Beckman Coulter). BrdU incorporation was analyzed by staining with a mouse anti-BrdU mAb. DNA was detected using Hoechst 33342. Stained cells were analyzed by SORP FACSAria.
Apoptosis analysis
Mouse BM cells were stained using an Annexin V-FITC Apoptosis Detection Kit (BD Biosciences) according to the manufacturer's instructions. Apoptotic cells were detected by SORP FACSAria.
BM immunohistochemistry
Frozen BM sections were prepared and immunostained according to the Kawamoto method (Kawamoto, 2003; . Frozen BM sections were fixed using dry ice/ethanol. Fixed sections were washed with PBS and stained using an Alexa Flour 647-conjugated anti-PLVAP antibody (diluted 1:100), 
Analysis of BM mesenchymal cells
Mesenchymal fractions were analyzed as described previously 
BMT and PB analysis
A total of 400,000 BMMNCs from C57BL/6-Ly5.2 mice or 500 LT-HSCs (CD150  + CD41  -CD48  -CD34 Flt3 -LSK) from C57BL/6-Ly5.1 mice, together with 4 × 10 5 BMMNCs from untreated C57BL/6-Ly5.1 or Ly5.2 mice, were transplanted into lethally irradiated (9.5 Gy) C57BL/6-Ly5.1 or Ly5.2 congenic mice, ) were determined at 2 and 4 weeks after transplantation.
Colony-forming cell assays
Cells were plated ( were incubated at 37°C in 5% CO 2 . Colony numbers were assessed at day 7. Colonies derived from HPP-CFCs (colony size > 2 mm) were assessed at day 14.
Liquid culture of LT-HSCs
CD34
-Flt3 -LSK cells were sorted and cultured in SF-O3 medium (Sankyo Junyaku) containing 100 ng/mL mouse stem cell factor (SCF; PeproTech) and 100 ng/mL human thrombopoietin (TPO; PeproTech) in non-coated 96-well round bottom plates (BD Falcon) for the indicated amount of time at 37°C in 5% CO 2 . 
Single cell colony assay
LTC-IC assay for c-di-GMP-treated stromal cells
OP9 cells (Nakano et al., 1994) were maintained in αMEM (Life Technologies) supplemented with 20%
FCS and 10 -6 M 2-mercaptoethanol. Cells (3 × 10 3 ) were cultured in a 96-well plate and treated with c-di-GMP or CMA for 3 days. Media was then replaced with MyeloCult M5300 supplemented with 10 -6 M hydrocortisone (Stem Cell Technologies). Thereafter, each well of cells was co-cultured with 500 sorted LT-HSCs (CD34 -Flt3 -LSK) at 33°C in 5% CO 2 for 14 days. Co-cultured LT-HSCs were collected and transferred to Methocult M3434 to assess colony-forming capacity.
Measurement of ATP concentration and LDH activity
Sorted cells (1-5 × 10 4 ) were lysed, and intracellular ATP concentration and LDH activity were measured using a Luciferase ATP Determination Kit (Sigma) and a LDH Cytotoxicity Detection Kit (TaKaRa), respectively, following the manufacturers' instructions.
Intracellular flow cytometry for phosphorylated ERK1/2 and phosphorylated AKT
BM cells were prepared and resuspended in 3 mL of PBS, fixed for 10 minutes at 37°C by adding 1 mL of 4% formaldehyde, and then chilled on ice for 1 minute. Cells were centrifuged and then permeabilized by the addition of 2 mL of ice-cold BD Perm III buffer (BD Biosciences) followed by incubation on ice for 8 resuspended in 100 µL of staining solution followed by Fc blocking with an anti-CD16/32 antibody (1:100) for 10 minutes at room temperature. An anti-CD51-biotin antibody (1:100) and isotype IgG
(1:100), an anti-phospho-ERK1/2 antibody (1:100), or an anti-phospho-AKT antibody (1:100) were then added to the cell suspension for 1 hour at room temperature. Cells were then stained with anti-CD31-FITC (1:100), anti-CD140a-APC (1:100), anti-Sca-1-PE-Cy7 (1:100), streptavidin-APC-Cy7
(1:100), and anti-rabbit IgG-PE (1:100) antibodies for 30 minutes at room temperature.
BM-derived macrophage culture
BMMNCs were collected and Gr-1 -Mac-1 + monocytes were sorted using a FACS Aria system.
Monocytes ( 1×10 6 ) were cultured in 10 mL of DMEM (Sigma) supplemented with 10% FCS and 100 ng/mL M-CSF (R&D Systems) for 12 days at 37ºC in 5% CO 2 and then harvested for analysis.
Quantitative RT-PCR
Quantitative PCR was performed as described previously (Takubo et al., 2008) . cDNA equivalent to 1000 cells served as the template for each PCR reaction. PCR primers were purchased from TaKaRa
Bio. 
cDNA microarray analysis
GSEA
Normalized expression data were assessed using GSEA v2.0.13 software (Broad Institute). Gene sets were obtained from the Molecular Signatures Database v4.0 distributed at the GSEA website (http://www.broadinstitute.org/gsea/msigdb/index.jsp). The number of permutations was set to 1000.
Gene sets with a nominal p-value < 0.05 and a false discovery rate q-value < 0.25 were considered statistically significant.
In vivo TGF-β β β β1 administration or inhibition
PBS or 800 ng of TGF-β1 was intravenously administered to mice for five consecutive days. For inhibition studies, 0.5 mg of Ly364947 or vehicle control (DMSO) was intraperitoneally administered to mice for three consecutive days.
In vivo NF-κ κ κ κB inhibition DMSO or 200 µg of Bay11-7082 was intraperitoneally administered to mice for three consecutive days.
Ex vivo CMA treatment
LT-HSCs (CD34 -Flt3 -LSK cells) were sorted from Ly5.2 + STING +/+ mice or STING -/-mice, and 10,000 cells were incubated in the presence of CMA or vehicle (DMSO) control.
Salmonella infection
Salmonella Enteritidis was a gift from Dr. Iñigo Lasa (The Agrobiotechnology Institute, Navarra).
Salmonella was spread on LB plates and incubated overnight at 37°C. A single colony was picked and incubated in LB medium for 3 more hours, and absorbance at 600 nm was assessed to estimate the number of CFUs. Mice were orally inoculated with 10 9 CFUs of Salmonella or PBS alone and sacrificed 5 days later for analysis. .5 Gy-irradiated Ly5.1 + recipients, which were treated with c-di-GMP 2 months later.
Generation of BM chimeric mice
Measurement of serum cytokines
The whole blood of mice treated with c-di-GMP or PBS was collected from the inferior vena cava after sacrifice and centrifuged using BD Microtainer blood collection tubes (BD Biosciences). The serum was subjected to an ELISA using a Quantikine ELISA Kit (R&D Systems) for G-CSF, IL-6, GM-CSF, IFN-γ, and TNF-α, and a VeriKine Mouse Interferon Alpha ELISA Kit for IFN-α (PBL). All procedures were performed according to the manufacturer's instructions.
Statistical analysis
Data are presented as the means ± SD, unless otherwise stated. Statistical significance was determined by Tukey's multiple comparison test. The two-tailed Student's t-test was used for experiments with two groups, and the log-rank test was used for survival data. *P < 0.05, **P < 0.01, ***P < 0.001, n.s. not significant, ND, not detected. two independent experiments).
*P < 0.05, **P < 0.01, ***P < 0.001, n.s. not significant. (A), (B) In vitro colony-forming assays in the presence or absence of c-di-GMP. In total, 10,000 whole BMMNCs, 150 LSK cells, and 150 LT-HSCs (CD34 -Flt3 -LSK) were analyzed, and the number of granulocyte-macrophage (GM), erythroid (E) , and mixed (Mixed) colonies was determined at day 7 (A).
HPP-CFCs were assessed after 14 days of culture (B) (mean ± SD, n = 3). (mean ± SD, n = 8).
*P < 0.05, **P < 0.01, and ***P < 0.001, n.s., not significant. (A) Gene sets enriched in MSCs from c-di-GMP-treated mice.
(B) Microarray analysis of osteoblast-specific transcription factors in MCSs from PBS-(Ctrl) or c-di-GMP
